Research programme: cannabinoid therapeutics- GB Sciences

Drug Profile

Research programme: cannabinoid therapeutics- GB Sciences

Alternative Names: BCTC - Makai Biotechnology; TRPV1 inhibitors

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Hawaii
  • Developer GB Sciences; Makai Biotechnology
  • Class Cannabinoids; Small molecules
  • Mechanism of Action Immunomodulators; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Heart failure; Inflammation
  • Research Pain

Most Recent Events

  • 10 Oct 2017 Early research in Pain in USA (unspecified route)
  • 23 May 2017 GB Sciences files for patent protection for Myrcene-containing complex mixtures for the treatment of chronic pain and heart therapies
  • 06 Feb 2017 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top